Výsledky vyhledávání

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial

Autor: Melvin Churchill, T. Gathany, Elizabeth C. Hsia, Paul Emery, Chenglong Han, Bernardo A. Pons-Estel, Yiying Zhou, Patrick Durez, Ingrid Strusberg, Peter Nash, Won Park, Stephen Xu, Jocelyn H. Leu, Roy Fleischmann, Eric Amante

Publikováno v: Arthritis Care & Research

Objective: To evaluate the safety and efficacy of golimumab through 5 years in adults with active rheumatoid arthritis (RA) who had not previously received methotrexate (MTX). Methods: In the GO-BEFORE study, 637 MTX-naive adult patients with active

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61b5995aace1e59b8a17de9a6704500f
https://doi.org/10.1002/acr.22759

Zobrazit plný text záznamu

Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1-Year and 2-Year Clinical, Radiologic, and Physical Function Findings

Autor: Mittie K. Doyle, Stephen Xu, Bernardo A. Pons-Estel, Paul Emery, Peter Nash, Patrick Durez, Zhong Wu, Roy Fleischmann, Ingrid Strusberg, W. Xu, Eric Amante, Won Park, Melvin Churchill, Elizabeth C. Hsia

Publikováno v: Arthritis Care & Research. 65:1732-1742

To assess 2-year golimumab efficacy/safety in patients with active rheumatoid arthritis (RA) who had never taken methotrexate (MTX).RA patients who had never taken MTX (n = 637) were randomized (1:1:1:1) to placebo + MTX (group 1), golimumab 100 mg +

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35648ae54e72b191176288519443d518
https://doi.org/10.1002/acr.22072

Zobrazit plný text záznamu

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

Autor: Peter Nash, Elizabeth C. Hsia, Paul Emery, Patrick Durez, Mahboob Rahman, Ingrid Strusberg, Roy Fleischmann, Melvin Churchill, Larry W. Moreland, Mittie K. Doyle, Sudha Visvanathan, W. Xu, Won Park, Eric Amante, Bernardo A. Pons-Estel

Publikováno v: Arthritis & Rheumatism. 60:2272-2283

Objective. To assess the safety and efficacy of golimumab in methotrexate (MTX)-naive patients with active rheumatoid arthritis (RA). Methods. MTX-naive patients with RA (n = 637) were randomized to receive placebo plus MTX (group 1), golimumab 100 m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d87fff39dc85749098ffc56bfdf03e
https://doi.org/10.1002/art.24638

Zobrazit plný text záznamu

97. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Methotrexate-NaïVe Patients with Rheumatoid Arthritis

Autor: Patrick Durez, Ingrid Strusberg, Peter Nash, Chenglong Han, Stephen Xu, Melvin Churchill, Paul Emery, Won Park, Roy Fleischmann, Tim Gathany, Bernardo A. Pons-Estel, Elizabeth C. Hsia, Yiying Zhou, Eric Amante

Publikováno v: Rheumatology. 53:i93-i93

randomized controlled trial (RCT)—the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) trial—to examine whether responses to intensive combination treatments in early RA differ by ACPA status. Methods: The CARDERA trial randomized 467 patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cbbd11d7c6f4ad009805996a42dc303
https://doi.org/10.1093/rheumatology/keu101.018

Zobrazit plný text záznamu

FRI0178 Five-year safety and efficacy of golimumab in methotrexate-naïve patients with rheumatoid arthritis: final study results of the phase 3, randomized, placebo-controlled go-before trial

Autor: Patrick Durez, Paul Emery, Ingrid Strusberg, T. Gathany, Elizabeth C. Hsia, Eric Amante, Won Park, R.M. Fleischmann, C. Han, Yiying Zhou, Melvin Churchill, Peter Nash, Stephen Xu, Bernardo A. Pons-Estel

Publikováno v: Annals of the Rheumatic Diseases. 72:A432.1-A432

Objectives Final 5yr safety and efficacy results of subcutaneous golimumab (GLM)+/-MTX evaluated in a phase 3 trial (GO-BEFORE) of MTX-naive pts with rheumatoid arthritis (RA) are reported. Methods Pts were randomized to PBO+MTX, GLM 100mg+PBO, GLM 5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b5b91181f1609a9cc962d5bed6d619f7
https://doi.org/10.1136/annrheumdis-2013-eular.1305

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání